Zimbabwe has turned down a significant American healthcare agreement valued at $367m (272 million pounds) spanning five years due to Washington's insistence on confidential data.
This rejection came to light following a government memo dated December was disclosed, revealing that Head of State Emmerson Mnangagwa deemed the agreement was "skewed".
A government spokesman later explained that the US was requesting health data for research and commercial gain but was unwilling to guarantee the benefits from future medical innovations.
"We are forced to start the challenging and unfortunate task of winding down our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had donated over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged more talks to secure a deal agreeable to both sides so the nation's critical HIV treatment initiative can continue.
Broader Background
Zimbabwe's decision comes after a comparable case in Kenya, where a high court halted a similar health funding agreement after legal challenges were filed about the safety of Kenyans' health data.
Since resuming the presidency last year, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump argued its spending was "inefficient" and his administration was seeking direct bilateral deals to enhance transparency and accountability.
According to reports, Sixteen nations in Africa have to date agreed to similar agreements, constituting more than $18.3bn of fresh investment.
Details of the Rejected Deal
The funds for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation would have delivered extraordinary benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving HIV treatment through US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "asymmetrical".
"Our nation was requested to provide its genetic material and health information for a long time, without any equivalent promise of access to any scientific breakthroughs – such as new medicines or tests – that could result from that shared data," he stated.
"In essence, our nation would provide the basic resources for scientific discovery without any assurance that the final treatments would be available to our people should a future disease outbreak emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the global health body and its push of one-on-one deals were upending systems already set up through the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to manage potential pandemics.
"This system is intended to ensure that when a nation contributes its data, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the capability to develop them."
These objections over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We encourage ongoing discussions with our American counterparts on how subsequent collaboration could be arranged in a manner that honours the sovereignty and dignity of both nations."
Medical Community Reaction
A leading public health body expressed it understood the government's concerns, but recommended that talks need to persist since a large portion of the country's HIV programmes were funded by international support.
"Where specific concerns arise, such as those relating to information security or agreement terms, these can frequently be resolved via detailed discussion and mutually agreed protections," the group commented.
The halted deal underscores the continuing tensions between accepting much-needed international aid and protecting a country's data in an increasingly data-driven world.